# HANDOFF: M-6 Enhanced Radiation Modeling - Research Validation

**From:** Orchestrator
**To:** research-skeptic (Sylvia)
**Date:** December 8, 2025
**Priority:** QUALITY GATE 1 (BLOCKING)

---

## Context

M-6: Enhanced Radiation Modeling requires comprehensive research validation before implementation proceeds. Research phase is complete, now entering Quality Gate 1.

**Proposal:** `/home/lizthedeveloper_gmail_com/ai_game_theory_simulation/openspec/changes/enhanced-radiation-modeling/proposal.md`

**Research Output:** `/home/lizthedeveloper_gmail_com/ai_game_theory_simulation/research/radiation_health_effects_20251208.md`

---

## Research Summary

Comprehensive literature review completed covering:

1. **ICRP 103 tissue weighting factors** (w_T)
   - High sensitivity: 0.12 (stomach, colon, lung, bone marrow, breast)
   - Medium sensitivity: 0.08 (gonads)
   - Low sensitivity: 0.04 (thyroid, liver, esophagus, bladder)
   - Minimal sensitivity: 0.01 (bone surface, skin, brain)

2. **Acute exposure LD50/60 thresholds**
   - No treatment: 4.0 Gy (50% mortality)
   - Supportive care: 6.0 Gy (50% mortality)
   - Intensive care: 8.0 Gy (50% mortality, optimistic)
   - Absolute mortality: 10+ Gy (near-certain death)

3. **Chronic exposure annual limits**
   - Occupational: 20 mSv/year (50 mSv max single year)
   - Public: 1 mSv/year

4. **Dose-Rate Effectiveness Factor (DREF)**
   - ICRP/UNSCEAR: DREF = 2.0
   - INWORKS (2020s): DREF = 1.0 (CONTESTED)
   - Dose-rate threshold: 0.1 Gy/min (6 Gy/hour)

5. **Tissue-specific cancer risk (ERR/Sv)**
   - Leukemia: 4.5 per Sievert
   - Solid cancers: 0.97 per Sievert
   - Gender: Women 2× more sensitive than men

6. **Medical evidence**
   - Hiroshima/Nagasaki LSS: 1 Gy → 47% cancer incidence increase
   - Chernobyl liquidators: 4× thyroid cancer baseline
   - Fukushima: < 5 mSv → no detectable increase

---

## Your Task (Quality Gate 1)

**Validate the research findings with critical skepticism.**

### Primary Questions

1. **DREF controversy:** ICRP says 2.0, INWORKS says 1.0. Which should we use? Is there contradictory evidence?

2. **LD50/60 treatment dependency:** Values vary 2× based on medical care (4.0 Gy → 8.0 Gy). For nuclear winter scenarios with degraded infrastructure, which value is appropriate?

3. **Low-dose linearity:** Recent 2024 research challenges Linear-No-Threshold (LNT) model below 100 mGy. Should we abandon LNT for low doses?

4. **Fukushima overdiagnosis:** Report says increased thyroid cancer from "screening effect" not radiation. Does this undermine cancer risk modeling at low doses?

5. **Tissue weighting granularity:** ICRP 103 provides detailed organ weights, but is 3-tier simplification (HIGH/MEDIUM/LOW) sufficient for nuclear war scenarios?

6. **Cancer time distribution:** Research uses Gaussian curve peaking at 25 years. Is this appropriate, or do different cancers have different time profiles?

7. **Gender differences:** Women 2× more sensitive - but ERR data is from mixed populations. Is this adjustment double-counting?

### Methodological Concerns

- **Source recency:** ICRP 103 is from 2007 (18 years old). Are there newer standards we missed?
- **LSS representativeness:** Japanese population, acute exposure. Does this generalize to chronic exposure in other populations?
- **Chernobyl data quality:** Liquidator dose reconstruction uncertain. How reliable is ERR = 0.38 per 100 mGy?
- **INWORKS controversy:** Why does recent study contradict ICRP DREF? What's going on?

### Validation Targets

**Historical benchmarks:**
- LSS: 1 Gy → 22% death increase, 47% cancer incidence increase
- Chernobyl: Thyroid cancer SIR = 4.33
- Fukushima: < 5 mSv → no detectable effect

**Can the proposed model reproduce these?** If not, why not?

---

## Success Criteria

**Grade B or higher required to proceed to implementation.**

**Grade A:** Research is sound, parameters justified, minimal concerns
**Grade B:** Minor issues identified, recommendations for refinement, proceed with caution
**Grade C:** Significant gaps, requires additional research before implementation
**Grade D:** Fatal methodological flaws, must pivot approach or reject feature

### Output Required

**File:** `/home/lizthedeveloper_gmail_com/ai_game_theory_simulation/reviews/radiation_health_effects_critique_20251208.md`

**Structure:**
1. Executive Summary (grade + key findings)
2. Strengths (what's well-supported)
3. Weaknesses (what's uncertain/contested)
4. Contradictory Evidence (papers that disagree)
5. Parameter Recommendations (conservative vs optimistic values)
6. Implementation Warnings (watch out for these failure modes)
7. Additional Research Needed (if any)
8. Decision: PROCEED / LOOP BACK / PIVOT / REJECT

---

## Next Steps (After Your Validation)

**If Grade B+:**
- T2.1: Tissue Weighting Implementation (feature-implementer)
- T2.2: Acute vs Chronic Exposure types
- T2.3: Dose-Rate Dependency (DREF)
- T2.4: Nuclear Winter Integration

**If Grade C:**
- Loop back to super-alignment-researcher for additional sources
- Address specific gaps you identify

**If Grade D:**
- Orchestrator decides: pivot to simpler model or reject feature

---

## Coordination

**Channel:** `research` (Matrix)
**Agent ID:** `@agent-sylvia:themultiverse.school`

**Please post status updates:**
- When you start validation
- If you find critical contradictory evidence
- When validation is complete

---

## Research Document Location

`/home/lizthedeveloper_gmail_com/ai_game_theory_simulation/research/radiation_health_effects_20251208.md`

**Key sections to focus on:**
- Section 4: DREF (contested)
- Section 2: LD50/60 (treatment dependency)
- Section 9: Implementation Recommendations
- Section 10: Research Gaps and Uncertainties

---

**Your critical eye is essential. This is a research simulation - we need parameters that hold up under scrutiny. Be harsh, be thorough, find the weak points.**

**- Orchestrator**
